English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 4 July 2018, 18:18 JST
Share:
    

Source: Eisai
Eisai Listed for 17th Consecutive Year in FTSE4GOOD Index Series
An Index for Socially Responsible Investment

TOKYO, July 4, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 17th consecutive year since its initial inclusion in 2002. The FTSE4Good Index Series is a global index series for socially responsible investment.

The FTSE4Good Index Series is designed to help investors integrate environmental, social and governance (ESG) factors into their investment decisions. Of the 14 themes evaluated, Eisai received particularly high scores in "Customer Responsibility", "Corporate Governance", "Anti-Corruption", "Water Use", "Climate Change" and "Labor Standards", among others. As of June 2018, a total of 925 companies from around the world have been selected for the FTSE4Good Developed Index, including 152 companies from Japan.

Along with being listed in the FTSE4Good Index Series, Eisai is also listed in the Dow Jones Sustainability Asia Pacific Index, another representative index for socially responsible investment, as well as the MSCI Japan Empowering Women Index (WIN), the FTSE Blossom Japan Index, and the MSCI Japan ESG Select Leaders Index, which are the three ESG investment indices for Japanese stocks adopted by the Government Pension Investment Fund (GPIF).

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. By strengthening its ESG initiatives and increasing non-financial value, Eisai is striving to sustainably enhance corporate value based on this corporate philosophy.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Related News
Friday, 25 July 2025, 13:31 JST
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment
Wednesday, 23 July 2025, 10:07 JST
Launch of Beova(R) Tablets in Thailand for Overactive Bladder
Tuesday, 22 July 2025, 11:56 JST
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer's Association International Conference 2025
2025年7月16日 14時40分 JST
エーザイ、抗アミロイドβ抗体レカネマブの創薬研究が「第 9 回バイオインダストリー大賞」を受賞
Wednesday, 16 July 2025, 14:50 JST
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab
More news >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575